Italia markets closed

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,8000-0,1300 (-4,44%)
Alla chiusura: 04:00PM EST
2,8500 +0,05 (+1,79%)
Dopo ore: 04:23PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,9300
Aperto2,8700
Denaro2,7700 x 3100
Lettera2,8900 x 800
Min-Max giorno2,7700 - 2,9200
Intervallo di 52 settimane2,2300 - 9,2700
Volume622.692
Media Volume672.572
Capitalizzazione366,562M
Beta (5 anni mensile)1,50
Rapporto PE (ttm)5,83
EPS (ttm)0,4800
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,00
  • GlobeNewswire

    Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

    CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference, which is being held at The Fontainebleau Miami Beach in Mi

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results

    CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared

  • GlobeNewswire

    Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022

    CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2022 financial results will be reported after the market closes on Wednesday, November 9th. Management will host a conference call at 5:00 p.m. Eastern Time on Nove